Therapy target
- Complaint relief or elimination of symptoms.
Therapy recommendations
- If necessary, analgesia until definitive therapy when the diagnosis is confirmed.
- Statin-associated muscle pain (SAMS) [guidelines: S1 guideline]: statin therapy (HMG-CoA reductase inhibitor) can be continued in a controlled manner at the same or reduced dose if
- Tolerable or no muscle symptoms are present, and
- Creatine kinase (CK): <10 times the upper norm.
Statin therapy should be discontinued:
- Intolerable symptoms*
- CK elevation: > 10 times the upper norm.
- Clinically relevant rhabdomyolysis (disintegration of striated muscle).
Coenzyme Q10: 30 mg
* Note: If there is no regression of symptoms after discontinuation of statin therapy, it may be immune-mediated necrotizing myopathy (NM; form of myositis/muscle inflammation), which is considered a rare complication of statin therapy. This necessitates immunosuppressive therapy.Clinical presentation: progressive proximal/axial weakness (difficulty standing), dysphagia (difficulty swallowing), or myalgias.
Supplements (dietary supplements; vital nutrients)
Appropriate dietary supplements should contain the following vital substances:
- Vitamins (vitamin D (calciferols))
- Trace elements (selenium* * , zinc* * )
- Other vital substances (coenzyme Q 10* * – under therapy with lipid lowering agents (lipid lowering agents)).
Legend
- * Deficiency symptoms
- * * Risk groups
